These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

154 related articles for article (PubMed ID: 31321793)

  • 1. Quality of life in patients with β-thalassemia: A prospective study of transfusion-dependent and non-transfusion-dependent patients in Greece, Italy, Lebanon, and Thailand.
    Cappellini MD; Kattamis A; Viprakasit V; Sutcharitchan P; Pariseau J; Laadem A; Jessent-Ciaravino V; Taher A
    Am J Hematol; 2019 Oct; 94(10):E261-E264. PubMed ID: 31321793
    [No Abstract]   [Full Text] [Related]  

  • 2. [Health status and quality of life in β-thalassemia adults in Marseille, France].
    Soubrier C; Jean E; De Sainte Marie B; Agouti I; Seguier J; Lavoipierre V; Clapasson C; Iline N; Gonin J; Giorgi R; Schleinitz N; Thuret I; Badens C; Bernit E
    Rev Med Interne; 2024 Apr; 45(4):187-193. PubMed ID: 38519305
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pilot study on the "quality of life" as reflected by psychosocial adjustment of children with thalassemia major undergoing iron-chelating treatment in western Taiwan.
    Kuo HT; Tsai MY; Peng CT; Wu KH
    Hemoglobin; 2006; 30(2):291-9. PubMed ID: 16798654
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Nephrolithiasis in beta thalassemia major patients treated with deferasirox: an advent or an adverse event? A single Greek center experience.
    Efthimia V; Neokleous N; Agapidou A; Economou M; Vetsiou E; Teli A; Perifanis V
    Ann Hematol; 2013 Jan; 92(2):263-5. PubMed ID: 22933235
    [No Abstract]   [Full Text] [Related]  

  • 5. Pilot study on parental stress and behavioral adjustment to the thalassemia major disease process in children undergoing iron-chelation in western Taiwan.
    Kuo HT; Peng CT; Tsai MY
    Hemoglobin; 2006; 30(2):301-9. PubMed ID: 16798655
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Beta-thalassemia.
    Rund D; Rachmilewitz E
    N Engl J Med; 2005 Sep; 353(11):1135-46. PubMed ID: 16162884
    [No Abstract]   [Full Text] [Related]  

  • 7. Impact of thalassemia major on patients and their families.
    Caro JJ; Ward A; Green TC; Huybrechts K; Arana A; Wait S; Eleftheriou A
    Acta Haematol; 2002; 107(3):150-7. PubMed ID: 11978936
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The Non-Adherence To Iron Chelation Therapy (ICT) Among Transfusion Dependent Thalassemia (TDT) Patients In Pakistan.
    Arif F; Qazi Z; Maqsood A
    J Pak Med Assoc; 2023 Sep; 73(9):1939. PubMed ID: 37817728
    [No Abstract]   [Full Text] [Related]  

  • 9. Non-transferrin-bound labile plasma iron and iron overload in sickle-cell disease: a comparative study between sickle-cell disease and beta-thalassemic patients.
    Koren A; Fink D; Admoni O; Tennenbaum-Rakover Y; Levin C
    Eur J Haematol; 2010 Jan; 84(1):72-8. PubMed ID: 19732137
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Deferiprone (GPO-L-ONE(®) ) monotherapy reduces iron overload in transfusion-dependent thalassemias: 1-year results from a multicenter prospective, single arm, open label, dose escalating phase III pediatric study (GPO-L-ONE; A001) from Thailand.
    Viprakasit V; Nuchprayoon I; Chuansumrit A; Torcharus K; Pongtanakul B; Laothamatas J; Srichairatanakool S; Pooliam J; Supajitkasem S; Suriyaphol P; Tanphaichitr VS; Tuchinda S
    Am J Hematol; 2013 Apr; 88(4):251-60. PubMed ID: 23460233
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Urinary iron excretion induced by intravenous infusion of deferoxamine in beta-thalassemia homozygous patients.
    Boturao-Neto E; Marcopito LF; Zago MA
    Braz J Med Biol Res; 2002 Nov; 35(11):1319-28. PubMed ID: 12426631
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The influence of hemochromatosis mutations on iron overload of thalassemia major.
    Longo F; Zecchina G; Sbaiz L; Fischer R; Piga A; Camaschella C
    Haematologica; 1999 Sep; 84(9):799-803. PubMed ID: 10477452
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Combined therapy with desferrioxamine and deferiprone in beta thalassemia major patients with transfusional iron overload.
    Daar S; Pathare AV
    Ann Hematol; 2006 May; 85(5):315-9. PubMed ID: 16450126
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effect of transfusion on lipid peroxidation products in the plasma of thalassemic patients.
    Sher GD; Bartfay WJ; Liu PP; Lehotay DC
    Transfusion; 1999 Mar; 39(3):333-4. PubMed ID: 10204599
    [No Abstract]   [Full Text] [Related]  

  • 15. Iron-chelating therapy for transfusional iron overload.
    Musallam KM; Taher AT
    N Engl J Med; 2011 Apr; 364(15):1476; author reply 1477. PubMed ID: 21488787
    [No Abstract]   [Full Text] [Related]  

  • 16. Iron Chelation Therapy as a Modality of Management.
    Aydinok Y
    Hematol Oncol Clin North Am; 2018 Apr; 32(2):261-275. PubMed ID: 29458731
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Daily alternating deferasirox and deferiprone therapy for "hard-to-chelate" beta-thalassemia major patients.
    Balocco M; Carrara P; Pinto V; Forni GL
    Am J Hematol; 2010 Jun; 85(6):460-1. PubMed ID: 20513129
    [No Abstract]   [Full Text] [Related]  

  • 18. Quality of life and survival of patients with beta-thalassemia major.
    Cao A
    Haematologica; 2004 Oct; 89(10):1157-9. PubMed ID: 15477196
    [No Abstract]   [Full Text] [Related]  

  • 19. Liver fibrosis and iron levels during long-term deferiprone treatment of thalassemia major patients.
    Wu SF; Peng CT; Wu KH; Tsai CH
    Hemoglobin; 2006; 30(2):215-8. PubMed ID: 16798646
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Thalassaemia-A global view.
    Hokland P; Daar S; Khair W; Sheth S; Taher AT; Torti L; Hantaweepant C; Rund D
    Br J Haematol; 2023 Apr; 201(2):199-214. PubMed ID: 36799486
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.